Anthem, Inc. (0HG8.L)
| Previous close | 434.03 |
| Open | 437.57 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 437.57 - 439.77 |
| 52-week range | 437.57 - 439.77 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 113.146B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 17.70 |
| EPS (TTM) | 24.73 |
| Earnings date | 19 Apr 2022 - 25 Apr 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Anthem's (ANTM) Q4 Earnings Beat Estimates, Improve Y/Y
Anthem's (ANTM) Q4 results reflect better revenues and a solid contribution from its Government Business and IngenioRx businesses, partly offset by escalating expenses.
- Zacks
Anthem (ANTM) Q4 Earnings Top Estimates
Anthem (ANTM) delivered earnings and revenue surprises of 0.59% and 0.91%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- Reuters
Anthem warns of elevated COVID costs in first quarter on Omicron surge
(Reuters) -U.S. health insurer Anthem Inc on Wednesday issued a conservative annual profit forecast and warned that the highly contagious Omicron variant was likely to drive up treatment, vaccination and testing costs in the first quarter. Since the start of the pandemic, profits of health insurers have come under pressure as huge costs related to direct COVID-19 treatment and tests cancel out any advantage gained from lower expenses due to delays in elective procedures. "We anticipate another year in which the overall cost of care will track above normalized levels driven by COVID-related treatment, vaccination and testing costs," Chief Financial Officer John Gallina said.
